Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease that encompasses a
spectrum of pathological conditions, ranging from simple steatosis (NAFL), nonalcoholic …

The progression of chronic liver diseases (CLD), irrespective of etiology, involves chronic
parenchymal injury, persistent activation of inflammatory response as well as sustained …

Liver cirrhosis is a major cause of death worldwide and is characterized by extensive
fibrosis. There are currently no effective antifibrotic therapies available. To obtain a better …

The natural history of cirrhosis is characterised by an asymptomatic compensated phase
followed by a decompensated phase, marked by the development of overt clinical signs, the …

Hepatic fibrosis is a dynamic process characterized by the net accumulation of extracellular
matrix resulting from chronic liver injury of any aetiology, including viral infection, alcoholic …

Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …

Progressive liver fibrosis, induced by chronic viral and metabolic disorders, leads to more
than one million deaths annually via development of cirrhosis, although no antifibrotic …

Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such
as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C …

Iterative liver injury results in progressive fibrosis disrupting hepatic architecture,
regeneration potential, and liver function. Hepatic stellate cells (HSCs) are a major source of …

Liver fibrosis and in particular cirrhosis are the major causes of morbidity and mortality of
patients with chronic liver disease. Their prevention or reversal have become major …